L'intérêt à découvert pour Structure Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Structure Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Structure Therapeutics (NASDAQ:GPCR) Stock, Rapport sur les intérêts à découvert

STRUCTURE THERAPEUTICS INC

Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics Inc

Scott Galloway, the <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45337334/scott-galloway-wants-to-cut-checks-for-rich-retirees-but-critics-say-his-fix-could-break-social-security">outspoken professor</a> and entrepreneur, says he gets it wrong all the time—and he doesn't try to hide it. &#8220;I bought Netflix at $12 and sold it at $10. Now it's at $1,100,&#8221; he said on a recent episode of the &#8220;<a href="https://www.youtube.com/watch?v=XwdaYTvncwk">My First Million</a>&#8221; podcast. &#8220;I can&#8217;t stand people who are constantly taking pictures of all their wins and posting them on social.&#8221;
<h2 class="wp-block-heading">Distressed Investing Over Hype Stocks</h2>
Despite that Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) miss, Galloway has racked up some big wins, mostly by betting on unpopular, overlooked assets. He says the best returns don't come from trendy stocks, but from distressed situations that smell, as he put it, &#8220;like urine.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
One of his best trades? Buying $10 million in <a href="https://www.benzinga.com/top-stories/25/05/45448569/ftx-to-distribute-over-5b-to-creditors-in-second-round-of-payouts-on-may-30">FTX bankruptcy claims</a> for $2.2 million after digging through the exchange&#8217;s filings. He figured their investment in <a href="https://www.benzinga.com/25/01/43127416/anthropic-gains-big-with-google-backing-aiming-for-60-billion-valuation-and-surging-ai-revenue">AI company Anthropic</a> was worth much more than creditors realized. "Crypto took off, everything they had invested in went crazy," he said. &#8220;Looks like we&#8217;re going to get 160 cents on the dollar.&#8221;
He admits there was risk, but also effort. &#8220;I&#8217;m that guy who reads bankruptcy filings,&#8221; he said.
<h2 class="wp-block-heading">From Vape Startups To Yellow Pages</h2>
Galloway&#8217;s biggest return came from helping bring vape company NJOY out of bankruptcy. He initially put in $2.5 million. After the company received the U.S. Food and Drug Administration approval and was bought by Altria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>), his stake turned into $75 million.
&#8220;We almost went to zero two or three times,&#8221; he said. &#8220;But that was hands down my best investment.&#8221;
Trending: <a href="https://www.benzinga.com/money/overplay">Mark Cuban Backs This Innovative Startup That Turns Videos into Games&nbsp; &#8212; Claim Your Share Now</a>
Another win came from dying yellow pages company Dex Media. He got in for about $4 million and sold after the business successfully pivoted into software. "What is less sexy than Yellow Pages?" he said.
Still, he doesn't shy away from his losses. He once invested $5 million in a healthcare texting company that went to zero in just 18 months. And he left $2 million on the table after selling covered calls on a stock that jumped right after earnings.
<h2 class="wp-block-heading">Shift Away From U.S. Stocks</h2>
Galloway is now moving away from U.S. equities, citing sky-high valuations and political instability. "[If] you think you're diversified because you're in an <a href="https://www.benzinga.com/money/what-is-an-index-fund">index fund</a>, you're not, because I believe the U.S. is going to go flat in the next decade," he said. &#8220;I&#8217;m going to be almost entirely out of the U.S. market within three or four months.&#8221;
He&#8217;s especially bullish on Europe, clarifying how everyone thinks Europe is overregulated and boring, but that&#8217;s exactly when you invest. &#8220;When something&#8217;s been left for dead,&#8221; he said.
Read Next:
<ul class="wp-block-list">
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

News

NFLX

'I Bought Netflix At $12 And Sold At $10. Now It's At $1,100, Says Scott Galloway, Hates When People Only Post Their Wins Online

Piper Sandler analyst Jessica Tassan maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $552 to $353.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on UnitedHealth Group, Lowers Price Target to $353

WIIM

VERO

VERO stock has given up its prior loss. Venus Concept shares were trading lower after the company announced it reached an agreement with Madryn Health to waive certain loan agreements for liquidity relief.

Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) has outperformed the market over the past 5 years by 11.53% on an annualized basis producing an average annual return of 24.43%. Currently, Carvana has a market capitalization of $45.76 billion. 
Buying $100 In CVNA: If an investor had bought $100 of CVNA stock 5 years ago, it would be worth $292.49 today based on a price of $338.91 for CVNA at the time of writing.
<h3>Carvana's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748960114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CVNA

Here's How Much You Would Have Made Owning Carvana Stock In The Last 5 Years

Joby Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares are trading higher Tuesday after the company announced a new agreement to explore distribution and service partnerships in <a href="https://www.benzinga.com/pressreleases/25/06/b45743529/abdul-latif-jameel-and-joby-agree-to-explore-opportunities-for-electric-aircraft-in-saudi-arabia">Saudi Arabia with Abdul Latif Jameel</a>.
What Happened: Electric vertical take-off and landing (eVTOL) air taxi company Joby Aviation signed a Memorandum of Understanding (MoU) with Abdul Latif Jameel to explore a potential distribution agreement for its electric aircraft in Saudi Arabia. 
The deal could lead to the delivery of up to 200 aircraft and related services valued at approximately $1 billion over the coming years. The companies noted that they also see potential long-term revenue opportunities across the Middle East.
"This collaboration is about bringing America&#8217;s leadership in electric air mobility to the world," said JoeBen Bevirt, founder and CEO of Joby Aviation.
&#8220;Together with Abdul Latif Jameel, we&#8217;re not just imagining a cleaner, safer, more efficient future—we&#8217;re building it. And there is no better partner to help unlock the extraordinary opportunity for air travel in the region.&#8221;
The collaboration is focused on enabling local air taxi services and building support infrastructure, including pilot training and MRO (Maintenance, Repair, and Overhaul) facilities. Joby and Abdul Latif Jameel will also work together to explore distribution and sales collaborations.
<h3 class="wp-block-heading">How To Buy JOBY Stock</h3>
By now you're likely curious about how to participate in the market for Joby Aviation &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Joby Aviation, which is trading at $8.35 as of publishing time, $100 would buy you 11.98 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
JOBY Price Action: Joby Aviation shares were up 8.6% at $8.13 at the time of publication Tuesday, according to <a class="" href="https://pro.benzinga.com/">Benzinga Pro</a>. The stock is now up over 60% over a one-year period and has seen heightened volume following news of its Middle East expansion efforts. Tuesday&#8217;s trading volume had already exceeded the company&#8217;s average session volume of approximately 13.8 million over the last 100 days at the time of publication.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45745834/nio-stock-drops-after-q1-results-and-outlook-disappoints-the-street-margins-shrink">Nio Stock Drops After Q1 Results And Outlook Disappoints The Street, Margins Shrink</a></li>
</ul>
Photo: courtesy of Joby Aviation.

Contracts

Global

Movers

JOBY

Joby Aviation Stock Is Taking Off Tuesday: What's Behind The Move?

- Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma
- ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy Compared to eBEACOPP, a Standard of Care Regimen in Europe
- Second Approval in Frontline Hodgkin Lymphoma Broadens ADCETRIS' Therapeutic Reach, Adding to Six Previously Approved, Distinct Indications for ADCETRIS in the European Union
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.takeda.com%2F&amp;esheet=54264219&amp;newsitemid=20250603992751&amp;lan=en-US&amp;anchor=Takeda&amp;index=1&amp;md5=06ff112e45cab46a48bacf2cabee3e82">Takeda</a> ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&amp;,%20esheet=54264219&amp;,%20newsitemid=20250603992751&amp;,%20lan=en-US&amp;,%20anchor=TSE%3A4502%2FNYSE%3ATAK&amp;,%20index=2&amp;,%20NYSE:%3Ca%20class=">TAK</a>) today announced that the European Commission (EC) approved ADCETRIS&#xAE; (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025.
The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma is based on the results of the randomized Phase 3 HD21 trial. The study met its co-primary safety and efficacy endpoints, with BrECADD demonstrating significantly superior safety as assessed by treatment-related morbidity (TRMB) and non-inferior progression-free survival (PFS) in comparison to escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP), a standard of care treatment in Europe.

Takeda Gains EC Approval For ADCETRIS In Combination With ECADD, Chemotherapy Regimen, In Adult Patients With Newly Diagnosed Stage IIb With Risk Factors/III/IV Hodgkin Lymphoma

<a href="https://www.bloomberg.com/news/articles/2025-06-03/fed-s-bostic-wants-more-progress-on-inflation-in-no-rush-to-cut?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-03/fed-s-bostic-wants-more-progress-on-inflation-in-no-rush-to-cut?embedded-checkout=true</a>

Economics

Federal Reserve

General

'Fed's Bostic Wants More Progress on Inflation, in No Rush to Cut'- Bloomberg

Volato Group, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) stock is trading higher Tuesday after the company announced its aircraft-trading program delivered $25.1 million in revenue for the <a href="https://www.benzinga.com//node/45743553">first-quarter of 2025.</a>
The company expects a comparable outcome in the second-quarter based on completed transactions.
&#8220;Our aircraft-trading program has matured into a reliable strategic capability,&#8221; said Matt Liotta, Co-Founder and CEO of Volato. 
&#8220;We&#8217;re now applying that expertise to selectively acquire charter-relevant aircraft and place them with top-tier operators. It&#8217;s a natural extension of our platform model—supporting operators, expanding access, and reinforcing the network effects behind Mission Control and Vaunt.&#8221;
Volato also announced that the company will begin leasing strategically selected aircraft to trusted third-party operators, aiming to create a new stream of revenue.
See Also: <a href="https://www.benzinga.com/markets/commodities/25/06/45746216/third-delay-in-mali-court-battle-over-barricks-gold-complex">Third Delay In Mali Court Battle Over Barrick&#8217;s Gold Complex</a>
SOAR Price Action: At the time of writing, Volato stock is trading 7.86% higher at $2.88, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjeg8j1sNWNAxU6ElkFHZRvMTEQFnoECAoQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro.</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

SOAR

Volato Stock Is Moving Higher Tuesday: What's Going On?

JMP Securities analyst Reni Benjamin downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Market Outperform to Market Perform.

Downgrades

BPMC

JMP Securities Downgrades Blueprint Medicines to Market Perform

Piper Sandler analyst Michael Lavery maintains Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) with a Neutral and lowers the price target from $2 to $1.8.

HAIN

Piper Sandler Maintains Neutral on Hain Celestial Group, Lowers Price Target to $1.8

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares are moving volatile Tuesday alongside several nuclear names after Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) signed a long-term deal with Constellation Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) for the <a href="https://www.benzinga.com/pressreleases/25/06/b45742156/constellation-meta-sign-20-year-deal-for-clean-reliable-nuclear-energy-in-illinois">supply of nuclear energy</a>.
What Happened: Meta and Constellation signed a 20-year power purchase agreement in which the Clinton Clean Energy Center will support Meta&#8217;s operations in the region with 1,121 megawatts of emissions-free nuclear energy.&nbsp;
The agreement supports the relicensing and continued operations of Constellation&#8217;s Clinton nuclear facility&nbsp;beginning in June of 2027. Under the deal, Clinton will add 30 megawatts of increased output from nuclear uprates.
&#8220;Last year, Constellation&#8217;s announced plan to restart the Crane Clean Energy Center became national news, but despite all of the interest and overwhelming support, a key question was missed: why did we let such a valuable plant close in the first place? We all know that the closure cost our community jobs, tax revenue, more pollution and higher prices,&#8221; said Joe Dominguez, president and CEO of Constellation Energy.
&#8220;We are proud to partner with Meta because they asked that important question, and even better, they figured out that supporting the relicensing and expansion of existing plants is just as impactful as finding new sources of energy. Sometimes the most important part of our journey forward is to stop taking steps backwards.&#8221;
Multiple nuclear names were getting a boost from the deal on optimism that similar deals could continue to be announced across the Industry.
Oklo is backed by OpenAI's&nbsp;Sam Altman, who recently&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/04/44937524/oklo-stock-falls-as-sam-altman-steps-down-as-board-chair-now-is-the-right-time" target="_blank" rel="noreferrer noopener">stepped down</a>&nbsp;as board chair to give the company more flexibility to go after partnerships with hyperscalers. The company <a href="https://www.benzinga.com/news/earnings/25/05/45392505/oklo-provides-q1-business-update-nuclear-startup-appoints-new-cto-company-says-its-targeting-plant-operations-in-late-2027-early-2028">said in May</a> that it's targeting plant operations in late 2027 or early 2028.
OKLO Price Action: <a href="http://benzinga.com/quote/OKLO" target="_blank" rel="noreferrer noopener">Oklo shares</a> were down 2.27% at $51.26 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45625025/oklo-ceo-says-recent-developments-surrounding-nuclear-could-move-company-timelines-forward">Oklo CEO Says Recent Developments Surrounding Nuclear Could Move Company Timelines Forward</a></li>
</ul>
Photo: Poetra.RH/Shutterstock.

OKLO

Oklo Stock Is Trading Volatile Tuesday: Here's Why

Wedbush analyst Daniel Ives reiterates Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Outperform and maintains $125 price target.

Reiteration

PEGA

Wedbush Reiterates Outperform on Pegasystems, Maintains $125 Price Target

CenterPoint Customers to Experience Improvements in Pre-Weather Event Notifications and Restoration Communications
Convey is proud to announce a major expansion of its relationship with CenterPoint Energy (NYSE:<a href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>). Convey, formerly known as Message Broadcast, is a longtime leader in providing customer engagement software for highly regulated industries and serves the largest utilities in North America; CenterPoint Energy is a leading electric and natural gas utility serving 7 million customers across Texas, Indiana, Ohio, and Minnesota.

Convey And Centerpoint Energy Expands Strategic Relationship To Enhance Customer Communications During Extreme Weather

Piper Sandler analyst Anna Andreeva maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and raises the price target from $280 to $315.

LULU

Piper Sandler Maintains Neutral on Lululemon Athletica, Raises Price Target to $315

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.04% to 42,286.94 while the NASDAQ rose 0.26% to 19,292.19. The S&amp;P 500 also rose, gaining, 0.04% to 5,938.09.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45744658/jim-cramer-recommends-nvidia-over-very-cheap-semiconductor-stock">Jim Cramer Recommends Nvidia Over &#8216;Very Cheap&#8217; Semiconductor Stock</a>
Leading and Lagging Sectors Information technology shares jumped by 0.6% on Tuesday.
In trading on Tuesday, real estate stocks fell by 1.1%.
Top Headline
Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) reported better-than-expected first-quarter earnings and raised its full-year outlook.
The general store operator said quarterly net sales increased 5.3% to $10.44 billion, barely missing the consensus of $10.64 billion. The company reported net income of $391.9 million, up 7.9%, with earnings of $1.78 per share, compared to $1.65 a year ago, beating the consensus of $1.58.
The company is updating its expectations for the year, primarily to reflect its outperformance in the first quarter and the tariff uncertainty. The company now expects fiscal year 2025 sales growth of approximately 3.7% to 4.7%, compared to its previous expectation of approximately 3.4% to 4.4%.
Dollar General revised earnings guidance from $5.10-$5.80 per share to $5.20-$5.80 compared to the consensus of $5.62.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares shot up 223% to $5.56. NewGenIvf Group recently announced a $30 million investment in Solana Digital Asset staking.</li>
<li>Shares of Ctrl Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) got a boost, surging 73% to $8.50.</li>
<li>Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares were also up, gaining 51% to $2.1401 after the company published key clinical efficacy data regarding its Rigosertib oncology asset.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Huachen AI Parking Management Technology Holding Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) shares dropped 29% to $2.87.</li>
<li>Shares of ModivCare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) were down 21% to $1.7301 after jumping 96% on Monday.</li>
<li>Safe and Green Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGD#NASDAQ">SGD</a>) was down, falling 17% to $0.9994. Safe and Green Development announced it has completed its acquisition of Resource Group US Holdings LLC.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $63.10 while gold traded down 0.9% at $3,367.80.
Silver traded down 0.6% to $34.480 on Tuesday, while copper slipped 0.1% to $4.8550.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 declined 0.1%, while Spain's IBEX 35 Index fell 0.7%. London's FTSE 100 rose 0.1%, Germany's DAX 40 gained 0.3% and France's CAC 40 fell 0.1% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei falling 0.06%, Hong Kong's Hang Seng Index jumping 1.53%, China's Shanghai Composite gaining 0.43% and India's BSE Sensex declining 0.78%.
Economics
<ul class="wp-block-list">
<li>U.S. job openings increased by 191,000 to 7.391 million in April, compared to market expectations of 7.10 million.</li>
<li>The US Logistics Manager's Index climbed to 59.4 in May from 58.8 in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45745163/how-to-earn-500-a-month-from-hewlett-packard-enterprise-stock-ahead-of-q2-earnings-2">How To Earn $500 A Month From Hewlett Packard Enterprise Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Intraday Update

Markets

HCAI

MCTR

MODV

NIVF

TRAW

US Stocks Mixed; Dollar General Posts Upbeat Earnings

RENB

Renovaro shares are trading higher after the company announced its subsidiary, BioSymetrics, received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application titled "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions"

Wheels Up Experience shares are trading higher after the company announced it regained Nasdaq compliance.

Piper Sandler analyst Edward Tenthoff assumes Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Overweight rating and announces Price Target of $7.

Initiation

BMEA

Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7

TRVI

Trevi Therapeutics shares are trading lower after the company launched a $100 million public offering.

NESR

National Energy Services shares are trading lower after the company reported Q1 financial results and missed its adjusted EPS and revenue estimates.

Health Care

Management

Press Releases

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Comments

Structure Therapeutics

Intérêt court

Structure Therapeutics (NASDAQ:GPCR) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL